# Itepekimab (sar440340) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/itepekimab-sar440340

> The next catalyst for itepekimab (sar440340), sponsored by Sanofi (SNY), is its topline data readout, Feb to May 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | itepekimab (sar440340) |
| Codes | REGN3500, SAR440340 |
| Sponsor | Sanofi (SNY) https://sec-api.dev/companies/sny/catalysts |
| Indications | [Bronchiectasis](https://sec-api.dev/indications/bronchiectasis), [Chronic Obstructive Pulmonary Disease](https://sec-api.dev/indications/chronic-obstructive-pulmonary-disease), [Chronic Rhinosinusitis With Nasal Polyps](https://sec-api.dev/indications/chronic-rhinosinusitis-with-nasal-polyps), [Chronic Rhinosinusitis Without Nasal Polyps](https://sec-api.dev/indications/chronic-rhinosinusitis-without-nasal-polyps) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### September 16, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Bronchiectasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06280391 (A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-16 (ACTUAL); Lead Sponsor Sanofi; Results First Posted 2026-10-07." https://clinicaltrials.gov/study/NCT06280391

### March 31, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Chronic Rhinosinusitis Without Nasal Polyps.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06691113 (A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-03-31 (ACTUAL); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06691113

### September 10, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Chronic Obstructive Pulmonary Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06208306 (A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-10 (ACTUAL); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06208306

### Sep to Dec 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Chronic Obstructive Pulmonary Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06208306 (A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-10 (ACTUAL); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06208306

### September 23, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Chronic Rhinosinusitis With Nasal Polyps.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06834347 (A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-23 (ACTUAL); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06834347

### Sep to Dec 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Chronic Rhinosinusitis With Nasal Polyps.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06834347 (A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-23 (ACTUAL); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06834347

### September 24, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Chronic Rhinosinusitis With Nasal Polyps.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06834360 (A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-24 (ACTUAL); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06834360

### Sep to Dec 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Chronic Rhinosinusitis With Nasal Polyps.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06834360 (A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-24 (ACTUAL); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06834360

### October 7, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 2. Indication: Bronchiectasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06280391 (A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-16 (ACTUAL); Lead Sponsor Sanofi; Results First Posted 2026-10-07." https://clinicaltrials.gov/study/NCT06280391?tab=results

### Feb to May 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Chronic Rhinosinusitis With Nasal Polyps.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07424144 (An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-17 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07424144

### February 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Chronic Rhinosinusitis With Nasal Polyps.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07424144 (An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-17 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07424144

## Same indication

- [Fasenra (benralizumab)](https://sec-api.dev/pdufa/benralizumab) (AZN)
- [GSK3862995B](https://sec-api.dev/pdufa/gsk3862995b) (GSK)
- [Lunsekimig](https://sec-api.dev/pdufa/lunsekimig) (SNY)
- [TEZSPIRE® (tezepelumab)](https://sec-api.dev/pdufa/tezepelumab) (AZN)
- [Tozorakimab dose regimen 1](https://sec-api.dev/pdufa/tozorakimab-dose-regimen-1) (AZN)
- [Treatment a : budesonide, glycopyrronium, and formoterol fumarate](https://sec-api.dev/pdufa/treatment-a-budesonide-glycopyrronium-and-formoterol) (AZN)
- [Verekitug](https://sec-api.dev/pdufa/verekitug) (UPB)
- [Verekitug (upb-101)](https://sec-api.dev/pdufa/verekitug-upb-101) (UPB)

Calendar months: [February 2027](https://sec-api.dev/fda-calendar/2027-02)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/itepekimab-sar440340.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Itepekimab (sar440340) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/itepekimab-sar440340

```bibtex
@misc{secapidev_pdufa_itepekimab_sar440340_20261116,
  title        = {Itepekimab (sar440340) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/itepekimab-sar440340}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_itepekimab_sar440340_20261116","title":"Itepekimab (sar440340) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/itepekimab-sar440340","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
